Marisa Wexler, MS, senior science writer —

The Michael J. Fox Foundation for Parkinson’s Research (MJFF) has awarded a $4.5 million grant to Nine Square Therapeutics to advance the development of potential treatments for a genetic form of Parkinson’s disease. “The Michael J. Fox Foundation grant will go toward accelerating the identification of drug…

People with Parkinson’s disease commonly experience stigma associated with the disorder, and if clinicians are to provide proper care for patients, it’s crucial for them to be proactive about addressing such stigma. That’s the argument made by a team of scientists from the U.S. and Canada in a new…

A treatment that works to stimulate the brain using weak magnetic waves effectively eased symptoms in a mouse model of Parkinson’s disease, a new study reports. Researchers hope to start a small-scale study soon testing this treatment in people. “The technology is proven and it’s harmless and we want…

People with Parkinson’s disease who have more severe nonmotor symptoms are less likely to feel empowered to manage their own disease, and also are less likely to get regular physical exercise, a new study shows. These findings “suggest that to promote physical activity and patient activation there is a…

People with a specific variation in a gene that helps control the immune system are less likely to develop Parkinson’s disease and other neurological disorders, a new study reports. Scientists think that people carrying this genetic variant might benefit from vaccines that could help to delay the progression of…

A mutation in the GBA1 gene is associated with an increased risk of Parkinson’s disease among people of African ancestry, a new study shows. While other mutations in GBA1 have previously been linked with Parkinson’s, this mutation, which is particularly common in people of African ancestry, has not been associated before with…

ND0612, a formulation of levodopa/carbidopa delivered continuously under the skin by a pump, was more effective than standard oral levodopa/carbidopa at controlling motor symptoms of Parkinson’s disease without causing problematic side effects. Those top-line findings from the Phase 3 BouNDless clinical trial were announced earlier this year,…

Treatment with the cell therapy bemdaneprocel (BRT-DA01) led to reductions in motor symptom severity for people with Parkinson’s disease in a small clinical trial, according to data announced by BlueRock Therapeutics, its developer. “We are excited to be sharing the results of this Phase I [trial] and look…

The COVID-19 pandemic has had some negative physical and social impacts on the overall well-being of people with Parkinson’s disease, a new study highlights. Therefore, it’s important for clinicians to help patients get social support, not just address physical symptoms of the disease as pandemic-related restrictions ease, researchers wrote…

Rates of Parkinson’s disease progression and treatment response may differ among patients depending on whether the disease primarily affects the dominant or nondominant side of the body, a small study of typing skills in patients new to dopaminergic therapy suggests. “These findings suggest that the relationship between side of…